Home Industries Market Insights About Us Publisher Contact us

Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity

Published Date : 30-Jul-2021

Report Id : HNY198723

Pages : 163

Region: Worldwide

Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 87 tables and 87 figures, this 163-page report “Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Region.
Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants
Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Monoclonal Antibodies
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Corticosteroids
• Adrenocorticotropic Hormone
• Other Drug Classes
Based on Drug Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Large-molecule Drugs
• Small-molecule Drugs
Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Oral Administration
• Parenteral Administration
Based on MS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Global Market by Drug Type 43
3.1 Market Overview by Drug Type 43
3.2 Immunomodulators 45
3.3 Immunosuppressants 47
4 Segmentation of Global Market by Drug Class 49
4.1 Market Overview by Drug Class 49
4.2 Monoclonal Antibodies 51
4.3 Interferon Beta 52
4.4 Sphingosine 1 Phosphate Receptor Modulators 53
4.5 Mixed Polymers 54
4.6 NF-κB Inhibitor 55
4.7 Pyrimidine Synthesis Inhibitor 56
4.8 Corticosteroids 57
4.9 Adrenocorticotropic Hormone 58
4.10 Other Drug Classes 59
5 Segmentation of Global Market by Drug Category 60
5.1 Market Overview by Drug Category 60
5.2 Large-molecule Drugs 62
5.3 Small-molecule Drugs 63
6 Segmentation of Global Market by Route of Administration 64
6.1 Market Overview by Route of Administration 64
6.2 Oral Administration 66
6.3 Parenteral Administration 67
7 Segmentation of Global Market by MS Type 68
7.1 Market Overview by MS Type 68
7.2 Relapsing-remitting MS (RRMS) 70
7.3 Primary-progressive MS (PPMS) 71
7.4 Secondary-progressive MS (SPMS) 72
7.5 Progressive-relapsing MS (PRMS) 73
8 Segmentation of Global Market by Distribution Channel 74
8.1 Market Overview by Distribution Channel 74
8.2 Hospital Pharmacies 76
8.3 Retail Pharmacies 77
8.4 Online Pharmacies 78
9 Segmentation of Global Market by Region 79
9.1 Geographic Market Overview 2020-2027 79
9.2 North America Market 2020-2027 by Country 83
9.2.1 Overview of North America Market 83
9.2.2 U.S. 86
9.2.3 Canada 89
9.2.4 Mexico 91
9.3 European Market 2020-2027 by Country 93
9.3.1 Overview of European Market 93
9.3.2 UK 96
9.3.3 France 98
9.3.4 Germany 100
9.3.5 Spain 102
9.3.6 Italy 104
9.3.7 Russia 106
9.3.8 Rest of European Market 108
9.4 Asia-Pacific Market 2020-2027 by Country 110
9.4.1 Overview of Asia-Pacific Market 110
9.4.2 China 113
9.4.3 Japan 115
9.4.4 India 118
9.4.5 Australia 120
9.4.6 South Korea 122
9.4.7 Rest of APAC Region 124
9.5 South America Market 2020-2027 by Country 126
9.5.1 Argentina 129
9.5.2 Brazil 131
9.5.3 Chile 133
9.5.4 Rest of South America Market 135
9.6 MEA Market 2020-2027 by Country 136
9.6.1 UAE 139
9.6.2 Saudi Arabia 141
9.6.3 South Africa 143
9.6.4 Other National Markets 145
10 Competitive Landscape 146
10.1 Overview of Key Vendors 146
10.2 New Product Launch, Partnership, Investment, and M&A 149
10.3 Company Profiles 150
Abbvie, Inc. 150
Acorda Therapeutics Inc. 152
Bayer AG 153
Biogen Inc. 154
Bristol-Myers Squibb Company 155
F. Hoffmann-La Roche Ltd. 156
Merck KgaA 157
Mylan NV 158
Novartis AG 159
Pfizer Inc. 160
Sanofi SA 161
Teva Pharmaceutical Industries Ltd. 162
RELATED REPORTS 163
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 18
Figure 4. Global Multiple Sclerosis Drugs Market, 2017-2027, $ mn 21
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Global Multiple Sclerosis Drugs Market 26
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 29
Figure 9. Primary Restraints and Impact Factors of Global Multiple Sclerosis Drugs Market 31
Figure 10. Investment Opportunity Analysis 36
Figure 11. Porter’s Fiver Forces Analysis of Global Multiple Sclerosis Drugs Market 39
Figure 12. Breakdown of Global Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 43
Figure 13. Contribution to Global 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 44
Figure 14. Global Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn 45
Figure 15. Global Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn 47
Figure 16. Breakdown of Global Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 50
Figure 17. Contribution to Global 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%) 50
Figure 18. Global Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn 51
Figure 19. Global Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn 52
Figure 20. Global Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn 53
Figure 21. Global Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn 54
Figure 22. Global Multiple Sclerosis Drugs Market: NF-κB Inhibitor, 2017-2027, $ mn 55
Figure 23. Global Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn 56
Figure 24. Global Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn 57
Figure 25. Global Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn 58
Figure 26. Global Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn 59
Figure 27. Breakdown of Global Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 60
Figure 28. Contribution to Global 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%) 61
Figure 29. Global Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn 62
Figure 30. Global Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn 63
Figure 31. Breakdown of Global Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 64
Figure 32. Contribution to Global 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%) 65
Figure 33. Global Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn 66
Figure 34. Global Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn 67
Figure 35. Breakdown of Global Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 68
Figure 36. Contribution to Global 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%) 69
Figure 37. Global Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn 70
Figure 38. Global Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn 71
Figure 39. Global Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn 72
Figure 40. Global Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn 73
Figure 41. Breakdown of Global Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 74
Figure 42. Contribution to Global 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 75
Figure 43. Global Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn 76
Figure 44. Global Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn 77
Figure 45. Global Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn 78
Figure 46. Global Market Snapshot by Region 79
Figure 47. Geographic Spread of Worldwide Multiple Sclerosis Drugs Market, 2020-2027, % of Revenue 80
Figure 48. Contribution to Global 2021-2027 Cumulative Revenue by Region, Value ($ mn) and Share (%) 81
Figure 49. North American Multiple Sclerosis Drugs Market, 2017-2027, $ mn 84
Figure 50. Breakdown of North America Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 84
Figure 51. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 85
Figure 52. U.S. Multiple Sclerosis Drugs Market, 2017-2027, $ mn 87
Figure 53. Canada Multiple Sclerosis Drugs Market, 2017-2027, $ mn 89
Figure 54. Multiple Sclerosis Drugs Market in Mexico, 2017-2027, $ mn 91
Figure 55. European Multiple Sclerosis Drugs Market, 2017-2027, $ mn 94
Figure 56. Breakdown of European Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 94
Figure 57. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 95
Figure 58. Multiple Sclerosis Drugs Market in UK, 2017-2027, $ mn 96
Figure 59. Multiple Sclerosis Drugs Market in France, 2017-2027, $ mn 98
Figure 60. Multiple Sclerosis Drugs Market in Germany, 2017-2027, $ mn 100
Figure 61. Multiple Sclerosis Drugs Market in Spain, 2017-2027, $ mn 102
Figure 62. Multiple Sclerosis Drugs Market in Italy, 2017-2027, $ mn 104
Figure 63. Multiple Sclerosis Drugs Market in Russia, 2017-2027, $ mn 106
Figure 64. Multiple Sclerosis Drugs Market in Rest of Europe, 2017-2027, $ mn 108
Figure 65. Asia-Pacific Multiple Sclerosis Drugs Market, 2017-2027, $ mn 111
Figure 66. Breakdown of APAC Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 111
Figure 67. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 112
Figure 68. Multiple Sclerosis Drugs Market in China, 2017-2027, $ mn 113
Figure 69. Multiple Sclerosis Drugs Market in Japan, 2017-2027, $ mn 116
Figure 70. Multiple Sclerosis Drugs Market in India, 2017-2027, $ mn 118
Figure 71. Multiple Sclerosis Drugs Market in Australia, 2017-2027, $ mn 120
Figure 72. Multiple Sclerosis Drugs Market in South Korea, 2017-2027, $ mn 122
Figure 73. Multiple Sclerosis Drugs Market in Rest of APAC, 2017-2027, $ mn 124
Figure 74. South America Multiple Sclerosis Drugs Market, 2017-2027, $ mn 127
Figure 75. Breakdown of South America Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 127
Figure 76. Contribution to South America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 128
Figure 77. Multiple Sclerosis Drugs Market in Argentina, 2017-2027, $ mn 129
Figure 78. Multiple Sclerosis Drugs Market in Brazil, 2017-2027, $ mn 131
Figure 79. Multiple Sclerosis Drugs Market in Chile, 2017-2027, $ mn 133
Figure 80. Multiple Sclerosis Drugs Market in Rest of South America, 2017-2027, $ mn 135
Figure 81. Multiple Sclerosis Drugs Market in Middle East and Africa (MEA), 2017-2027, $ mn 137
Figure 82. Breakdown of MEA Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 137
Figure 83. Contribution to MEA 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 138
Figure 84. Multiple Sclerosis Drugs Market in UAE, 2017-2027, $ mn 139
Figure 85. Multiple Sclerosis Drugs Market in Saudi Arabia, 2017-2027, $ mn 141
Figure 86. Multiple Sclerosis Drugs Market in South Africa, 2017-2027, $ mn 143
Figure 87. Growth Stage of Global Multiple Sclerosis Drugs Industry over the Forecast Period 146

Request For Discount

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any), so we can get back to you with a solution

Buy Now

Single User

US$ 3300

Multi User

US$ 4700

Corporate User

US$ 6100

Related Reports

Global Multiple Sclerosis Drugs Market 2020-2027 b...

RD Code : HNY198723